CORALVILLE, Iowa, Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President
and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the the Rodman & Renshaw 19th Annual Global
Investment Conference being held September 10-12, 2017, at the Lotte New York Palace in New York City.
Details of KemPharm's presentation are as follows:
| Date: |
Monday, September 11, 2017 |
| Time: |
10:00 AM (ET) |
| Location: |
Lotte New York Palace, 455 Madison Avenue, New York, NY 10022 |
| Room: |
Louis Room, 4th Floor |
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through its LATTM (Ligand Activated Therapy) platform
technology. KemPharm utilizes its LATTM platform technology to generate improved prodrug versions of FDA-approved
drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm’s co-lead clinical development
candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the
treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone
product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
